- Home
- FRSX vs BRTX Comparison
FRSX vs BRTX Comparison
Compare FRSX & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRSX
- BRTX
- Stock Information
- Founded
- FRSX N/A
- BRTX 1997
- Country
- FRSX Israel
- BRTX United States
- Employees
- FRSX N/A
- BRTX N/A
- Industry
- FRSX Computer Software: Prepackaged Software
- BRTX Managed Health Care
- Sector
- FRSX Technology
- BRTX Health Care
- Exchange
- FRSX Nasdaq
- BRTX Nasdaq
- Market Cap
- FRSX N/A
- BRTX 11.3M
- IPO Year
- FRSX 2017
- BRTX N/A
- Fundamental
- Price
- FRSX $1.22
- BRTX $1.55
- Analyst Decision
- FRSX
- BRTX Strong Buy
- Analyst Count
- FRSX 0
- BRTX 1
- Target Price
- FRSX N/A
- BRTX $18.00
- AVG Volume (30 Days)
- FRSX 1.1M
- BRTX 101.9K
- Earning Date
- FRSX 11-29-2024
- BRTX 11-12-2024
- Dividend Yield
- FRSX N/A
- BRTX N/A
- EPS Growth
- FRSX N/A
- BRTX N/A
- EPS
- FRSX N/A
- BRTX N/A
- Revenue
- FRSX $473,000.00
- BRTX $377,000.00
- Revenue This Year
- FRSX N/A
- BRTX $482.76
- Revenue Next Year
- FRSX N/A
- BRTX $212.24
- P/E Ratio
- FRSX N/A
- BRTX N/A
- Revenue Growth
- FRSX 3.28
- BRTX 189.55
- 52 Week Low
- FRSX $0.57
- BRTX $1.03
- 52 Week High
- FRSX $1.64
- BRTX $3.67
- Technical
- Relative Strength Index (RSI)
- FRSX 81.71
- BRTX 54.98
- Support Level
- FRSX $0.61
- BRTX $1.40
- Resistance Level
- FRSX $1.28
- BRTX $1.60
- Average True Range (ATR)
- FRSX 0.10
- BRTX 0.10
- MACD
- FRSX 0.04
- BRTX 0.01
- Stochastic Oscillator
- FRSX 57.30
- BRTX 85.29
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.